A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

Completed · Phase 1

Conditions studied: Hepatic Impairment

In brief

A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on the Single-Dose Pharmacokinetics of Sitravatinib

Key facts

Study ID

NCT04772612

Run by

Mirati Therapeutics Inc.

People needed

30

Starts

2021-03-12

Expected to finish

2023-04-13

Last updated by the study team

2023-10-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

Where it is running

• Orange County Research Center — Tustin, California, United States
• Clinical Pharmacology of Miami — Miami, Florida, United States
• Orlando Clinical Research Center — Orlando, Florida, United States
• Nucleus Network — Saint Paul, Minnesota, United States
• Texas Liver Institute — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.